Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
First Claim
1. A method of treating a patient who has had a stroke, the method comprising intranasally administering to the patient umbilical cord tissue-derived cells in an amount effective to treat the stroke, wherein the cells are isolated from mammalian umbilical cord tissue substantially free of blood or are expanded in culture from a cell isolated from mammalian umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture, and wherein the cells do not produce CD117.
7 Assignments
0 Petitions
Accused Products
Abstract
This invention relates to methods of treating stroke by intranasal administration of umbilical cord tissue-derived cells, which are isolated from mammalian umbilical cord tissue substantially free of blood or expanded in culture from a cell isolated from mammalian umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, and do not produce CD117 and/or telomerase. The methods of the invention regenerate, repair and improve neural tissue and improve behavior and neurological function in stroke patients.
212 Citations
31 Claims
- 1. A method of treating a patient who has had a stroke, the method comprising intranasally administering to the patient umbilical cord tissue-derived cells in an amount effective to treat the stroke, wherein the cells are isolated from mammalian umbilical cord tissue substantially free of blood or are expanded in culture from a cell isolated from mammalian umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture, and wherein the cells do not produce CD117.
- 14. A method of treating a patient who has had a stroke, the method comprising intranasally administering to the patient a pharmaceutical composition comprising umbilical cord tissue-derived cells in an amount effective to treat the stroke, wherein the cells are isolated from mammalian umbilical cord tissue substantially free of blood or are expanded in culture from a cell isolated from mammalian umbilical cord tissue substantially free of blood, wherein the cells are capable of self-renewal and expansion in culture, and wherein the cells do not produce CD117.
Specification